In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Genentech gets NA rights to Altus' ALTU238

Executive Summary

Genentech has licensed exclusive North American development, manufacturing, and marketing rights to Altus Pharmaceuticals' (oral and injectable therapeutics for gastrointestinal and metabolic conditions) ALTU238. The Phase II compound is a hormone that is subcutaneously administered once a week to patients suffering from growth hormone deficiencies.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Biotechnology
    • Large Molecule
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register